Anne is a seasoned life sciences executive with over 25 years of experience in gene therapy and rare diseases. Her career has spanned academia, non-profit, and biotech industries, with a focus on translational sciences and personalized medicine. A pioneer in the field, Anne began her journey in the early 1990s at Imperial College, London, exploring the early concept of gene therapy for cystic fibrosis. In the early 2000s as an R&D leader, Anne was instrumental in establishing the first gene therapy program at Genethon, France, where she contributed to early proofs of concept and emergence of gene-based therapeutic technologies for various neuromuscular indications. As Program Director at Gensight Biologics (2013-2018), she drove the development of a groundbreaking optogenetic gene therapy drug. She joined Vivet Therapeutics from 2018 to 2025, as the Chief Development Officer before taking the role of Chief Operating Officer. As a founder of Ad hoc Biologics, she is now established as a consultant to support optimal development plan, roadmap and strategy for gene and cell therapies. Throughout her career, Anne has brought expertise in operational and strategic program and portfolio management, with a proven track record of driving progress in the life sciences industry. Holding a PhD in Human Genetics from University Paris-Cité and a Master's in Business and Strategic Management, Anne continues to drive growth and progress in the industry with passion for innovation and a keen interest in providing therapeutic solutions for untreated illnesses.